SAN FRANCISCO, March 19, 2020: Morgan Lewis represented Eli Lilly and Company in its agreement with AbCellera to co-develop antibody products for the treatment and prevention of COVID-19.
The collaboration will leverage Eli Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies and AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform Program.
The Morgan Lewis team advising Eli Lilly was led by partner Ben Pensak and associate Ben Rho, with assistance from associate Esther Phu.